Evidence map›Paper›PMID 29172153›Full record

ArticleStem cell research2017

Ajmaline blocks I

Duncan C Miller, Stephen C Harmer, Ariel Poliandri, Muriel Nobles, Elizabeth C Edwards, James S Ware, Tyson V Sharp, Tristan R McKay, Leo Dunkel, Pier D Lambiase and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Alterations of the Sialylation Machinery in Brugada Syndrome.International journal of molecular sciences · 2022
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Mechanisms of Arrhythmias in the Brugada Syndrome.International journal of molecular sciences · 2020
    Review
  14. Article
  15. Article
  16. Experimental Models of Brugada syndrome.International journal of molecular sciences · 2019
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Duncan C MillerWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Stephen C HarmerWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Ariel PoliandriWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Muriel NoblesWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Elizabeth C EdwardsNational Heart and Lung Institute, NIHR Royal Brompton Cardiovascular BRU, Imperial College London, London, UK.
James S WareNational Heart and Lung Institute, NIHR Royal Brompton Cardiovascular BRU, Imperial College London, London, UK.
Tyson V SharpBarts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Tristan R McKaySchool of Healthcare Science, Manchester Metropolitan University, Manchester, UK.
Leo DunkelWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Pier D LambiaseInstitute of Cardiovascular Science, UCL and Barts Heart Centre, London, UK.
Andrew TinkerWilliam Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Electronic address: a.tinker@qmul.ac.uk.
William Harvey Research Institute · GBQueen Mary University of London · GBNIHR Royal Brompton Cardiovascular Biomedical Research Unit · GBBritish Heart Foundation · GBManchester Metropolitan University · GB

Funding

British Heart Foundation FS/12/59/29756British Heart Foundation RG/15/15/31742British Heart Foundation SP/15/9/31605Medical Research Council MC_UP_1102/20National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/L001780/1Wellcome Trust WT 107469
6 · The paper itself

Abstract

The class Ia anti-arrhythmic drug ajmaline is used clinically to unmask latent type I ECG in Brugada syndrome (BrS) patients, although its mode of action is poorly characterised. Our aims were to identify ajmaline's mode of action in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs), and establish a simple BrS hiPSC platform to test whether differences in ajmaline response could be determined between BrS patients and controls. Control hiPSCs were differentiated into spontaneously contracting cardiac clusters. It was found using multi electrode array (MEA) that ajmaline treatment significantly lengthened cluster activation-recovery interval. Patch clamping of single CMs isolated from clusters revealed that ajmaline can block both I

Indexed as

AdultAjmalineAnti-Arrhythmia AgentsBrugada SyndromeCell DifferentiationHeartHumansMaleMiddle AgedMyocytes, CardiacNAV1.5 Voltage-Gated Sodium ChannelPatch-Clamp TechniquesPluripotent Stem CellsAjmalineAnti-Arrhythmia AgentsNAV1.5 Voltage-Gated Sodium ChannelSCN5A protein, humanActivation-recovery intervalAjmalineBrugada syndromehiPSC-cardiomyocytesI(Kr)I(Na)

Identifiers

PMID29172153
PMCPMC5727153
OpenAlexW2767259453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.